TY - JOUR
T1 - Next generation natural killer cells for cancer immunotherapy
T2 - the promise of genetic engineering
AU - Daher, May
AU - Rezvani, Katayoun
N1 - Funding Information:
The authors’ research efforts are funded in part by grants from the NIH (R01 CA211044-01 ), the Cancer Prevention Research Institute of Texas ( RSG-15-218-01-LIB ) and the American Cancer Society (ACS RSG-15-218-01-LIB ) and the generous philanthropic support of the MD Anderson Cancer Center Moon Shots programs. The authors wish to apologize to colleagues whose work could not be adequately cited or discussed due to space constraints.
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/4
Y1 - 2018/4
N2 - Recent advances in the field of cellular therapy have focused on autologous T cells engineered to express a chimeric antigen receptor (CAR) against tumor antigens. Remarkable responses have been observed in patients receiving autologous CD19-redirected T cells for the treatment of B-lymphoid malignancies. However, the generation of autologous products for each patient is logistically challenging and expensive. Extensive research efforts are ongoing to generate an off-the-shelf cellular product for the treatment of cancer patients. Natural killer (NK) cells are attractive contenders since they have potent anti-tumor activity, and their safety in the allogeneic setting expands the cell sources for NK cell therapy beyond an autologous one. In this review, we discuss advantages and limitations of NK cellular therapy, and novel genetic engineering strategies that may be applied to overcome some of the limitations. Next-generation engineered NK cells are showing great promise in the preclinical setting and it is likely that in the next few years CAR-engineered NK cells will be incorporated into the current armamentarium of cell-based cancer therapeutics.
AB - Recent advances in the field of cellular therapy have focused on autologous T cells engineered to express a chimeric antigen receptor (CAR) against tumor antigens. Remarkable responses have been observed in patients receiving autologous CD19-redirected T cells for the treatment of B-lymphoid malignancies. However, the generation of autologous products for each patient is logistically challenging and expensive. Extensive research efforts are ongoing to generate an off-the-shelf cellular product for the treatment of cancer patients. Natural killer (NK) cells are attractive contenders since they have potent anti-tumor activity, and their safety in the allogeneic setting expands the cell sources for NK cell therapy beyond an autologous one. In this review, we discuss advantages and limitations of NK cellular therapy, and novel genetic engineering strategies that may be applied to overcome some of the limitations. Next-generation engineered NK cells are showing great promise in the preclinical setting and it is likely that in the next few years CAR-engineered NK cells will be incorporated into the current armamentarium of cell-based cancer therapeutics.
UR - http://www.scopus.com/inward/record.url?scp=85044615820&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044615820&partnerID=8YFLogxK
U2 - 10.1016/j.coi.2018.03.013
DO - 10.1016/j.coi.2018.03.013
M3 - Review article
C2 - 29605760
AN - SCOPUS:85044615820
SN - 0952-7915
VL - 51
SP - 146
EP - 153
JO - Current Opinion in Immunology
JF - Current Opinion in Immunology
ER -